Immunotherapy and Targeted Therapy in Upper GI Cancers

Sam Klempner, MD, addresses what has changed in immunotherapy and targeted therapy in upper GI cancers, and reviews barriers that are preventing improvement. Dr. Klempner recalls a new option using Trastuzumab-Deruxtecan for HER2+ patients, and also explains how incorporation blood-based assays (ctDNA) may speed accrual and access.

Back to Symposium Page »


March 20, 2021

Created by

Scripps CME Connection

Related Presenters

Sam Klempner, MD

Sam Klempner, MD

GI Oncology
MGH Cancer Center
Massachusetts General Hospital

Dr. Klempner completed his residency in internal medicine at Brigham and Women’s Hospital/Harvard Medical School, followed by a combined hematology-oncology fellowship at Beth Israel Deaconess Medical Center/Harvard Medical School.  While ...

View full profile